What is Citius Oncology, Inc. (CTOR) stock price today?

Citius Oncology, Inc. (CTOR) currently trades at $0.88 per share. The stock has a market capitalization of $77.43M and a P/E ratio of —x.

Is CTOR stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Citius Oncology, Inc. has a Smart Value Score of 22/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Citius Oncology, Inc.'s revenue and earnings?

Citius Oncology, Inc. has trailing twelve-month (TTM) revenue of $3.94M with profit margins of 0.00%. Earnings per share (EPS) is $-0.31.

CTOR

Citius Oncology, Inc.

NASDAQ: CTOR · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$0.88

+2.31% today

Updated 2026-04-30

Market cap

$77.43M

P/E ratio

—

P/S ratio

19.63x

EPS (TTM)

$-0.31

Dividend yield

—

52W range

$0 – $6

Volume

0.3M

Market cap

$77.43M

P/E ratio

—

P/S ratio

19.63x

EPS (TTM)

$-0.31

Dividend yield

—

52W range

$0 – $6

Volume

0.3M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

5.0

Quality

C+

2.5

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →201 stocks currently score above 75

Price targets

Analyst target

$6.00

+581.90%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy0 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Thin margins at 0.00%

- Negative free cash flow $-7.35M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$3.94M
Net income	$-10.87M	$-12.70M	$-21.15M	$-24.76M	$-5.53M
EPS	—	—	—	—	$-0.31
Free cash flow	$-47968.00	$-601308.00	$126349.00	$-5.49M	$-7.35M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
CTOR	$77.43M	22	4.3	2.5	5.0	5.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Citius Oncology, Inc. trades at $0.88. Our Smart Value Score of 22/100 indicates the stock is weak. TTM revenue stands at $3.94M.

Frequently asked questions

What is Citius Oncology, Inc.'s stock price?

Citius Oncology, Inc. (CTOR) trades at $0.88.

Is Citius Oncology, Inc. overvalued?

Smart Value Score 22/100 (Grade F, Strong Sell).

What is the price target of Citius Oncology, Inc. (CTOR)?

The analyst target price is $6.00, representing +581.9% upside from the current price of $0.88.

What is Citius Oncology, Inc.'s revenue?

TTM revenue is $3.94M.

Company info

SectorHEALTHCARE

IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio19.63x

ROE-47.40%

Beta3.43

50D MA$0.87

200D MA$1.38

Shares out0.09B

Float0.01B

Short ratio—

Avg volume0.3M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

CTOR vs LLY →CTOR vs JNJ →CTOR vs ABBV →Stock screener →